BSF Enterprise PLC
("BSF" or the "Company")
Publication of New Research
BSF (LSE: BSFA; OTCQB: BSFAF), the Main Market listed biotech company and the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to inform shareholders that a new research note on the Company has recently been published by Shard Capital Partners LLP.
The note can be found on the Company's website, www.bsfenterprise.com, or via the Shard Portal.
-Ends-
For further enquiries, please visit www.bsfenterprise.com or contact:
|
BSF Enterprise PLC |
Via SEC Newgate below |
|
Che Connon - CEO & Executive Director Geoff Baker - Executive Director |
|
|
Shard Capital (Broker) |
|
|
Damon Heath Isabella Pierre |
0203 971 7000 0207 1869 927 |
|
SEC Newgate (Financial Communications) |
|
|
Bob Huxford Elisabeth Cowell George Esmond |
020 3757 6882 BSF@secnewgate.co.uk |
ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.
Notes to Editors
BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.
It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it has produced the UK's first high quality lab-grown meat from its laboratory using its technology.
BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.